EGFR and urinary bladder carcinoma: When we treated T24 human bladder cancer cells with 5 μM of these EGFR inhibitors, the CCK-8 assay showed that neither lapatinib nor gefitinib could reduce cell viability in a time-dependent manner (Figure 1A).